The complete guide for pharma IP teams, portfolio managers, R&D leads, and institutional investors on extracting maximum asset value from […]
Off-Label Drugs and Repurposing: The Full IP, Regulatory, and Commercial Playbook Read Post »
Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of
DrugPatentWatch and Bloomberg: Are there too many generic patent challenges? Read Post »
One of our clients, the Belarus Republican Scientific and Technical Library recently posted an article on how they support innovation.
Customer Success: DrugPatentWatch for Your Library Read Post »
How pharma IP teams, portfolio managers, and R&D leads identify, evaluate, and time market entry opportunities across branded, 505(b)(2), and
Biopharmaceutical Market Entry: The Complete IP, ANDA, and 505(b)(2) Playbook Read Post »
EXECUTIVE SUMMARY When a patent expires on the first-in-class drug in a therapeutic area, two things happen simultaneously. The originator’s
The pharmaceutical business operates on a fundamental cycle of innovation, patent-protected exclusivity, and eventual commoditization. For executives in business development,
1. The Structural Economics of Pharmaceutical Outsourcing Why Vertical Integration Failed The pharmaceutical industry did not arrive at its current
1. Why Most Drug Launches Fail Before They Begin Roughly two-thirds of new drug launches miss their first-year sales forecasts,
The Definitive Pharmaceutical Drug Launch Playbook: Every Critical Mistake, Dissected Read Post »
The Drug Price Competition and Patent Term Restoration Act of 1984 was not, in any conventional sense, a health policy
Sign in or create a free account to read this DrugPatentWatch article
